Trials / Completed
CompletedNCT02813408
A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants
Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 226 (actual)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study of metastatic castration-resistant prostate cancer (mCRPC) participants is to explore whether or not there are differences between participants treated with abiraterone acetate and enzalutamide on the health-related quality of life (HRQoL), Fatigue, Pain, Cognitive function and medical resource use (MRU).
Conditions
Timeline
- Start date
- 2016-05-03
- Primary completion
- 2018-03-21
- Completion
- 2018-03-21
- First posted
- 2016-06-27
- Last updated
- 2019-05-24
Locations
26 sites across 3 countries: Denmark, France, United Kingdom
Source: ClinicalTrials.gov record NCT02813408. Inclusion in this directory is not an endorsement.